Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma

Hájek, R, Minařík, J, Straub, J et al. (33 more authors) (2021) Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncology. fon-2020-1225. ISSN 1479-6694

Abstract

Metadata

Authors/Creators:
  • Hájek, R
  • Minařík, J
  • Straub, J
  • Pour, L
  • Jungova, A
  • Berdeja, JG
  • Boccadoro, M
  • Brozova, L
  • Spencer, A
  • Rhee, FV
  • Vela-Ojeda, J
  • Thompson, MA
  • Abonour, R
  • Chari, A
  • Cook, G ORCID logo https://orcid.org/0000-0003-0223-3652
  • Costello, CL
  • Davies, FE
  • Hungria, VTM
  • Lee, HC
  • Leleu, X
  • Puig, N
  • Rifkin, RM
  • Terpos, E
  • Usmani, SZ
  • Weisel, KC
  • Zonder, JA
  • Bařinová, M
  • Kuhn, M
  • Šilar, J
  • Čápková, L
  • Galvez, K
  • Lu, J
  • Elliott, J
  • Stull, DM
  • Ren, K
  • Maisnar, V
Copyright, Publisher and Additional Information: © 2021 Roman Hájek. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Keywords: effectiveness; ixazomib; multiple myeloma; proteasome inhibitor; relapsed/refractory; routine clinical practice
Dates:
  • Accepted: 1 March 2021
  • Published (online): 26 March 2021
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Inst of Clinical Trials Research (LICTR) (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 13 May 2021 15:22
Last Modified: 25 Jun 2023 22:39
Status: Published online
Publisher: Future Medicine
Identification Number: https://doi.org/10.2217/fon-2020-1225
Related URLs:

Download

Export

Statistics